An interventional study of Mandibular Oral Repositioning Appliance in Sleep, sponsored by University of Calgary. Recruiting at 1 site in Canada. Open to participants aged 40 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-01.
Sponsored by University of Calgary · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 104 studies in Sleep Initiation and Maintenance Disorders with a site in Canada — 21 open to participants now, 26 under way, 1 of them phase 3. Sleep Initiation and Maintenance Disorders · Canada.
Among the 104 studies in Sleep Initiation and Maintenance Disorders with a site in Canada, this one is the 78th largest by planned enrollment of the 96 interventional ones that give a count, is one of 2 that started in 2026, is one of 56 with no phase, reaches primary completion later than 10 of the 25 other live ones, and was the 103rd registered.
2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.
Browse Sleep Initiation and Maintenance Disorders studies →21 of the 104 studies in Sleep Initiation and Maintenance Disorders with a site in Canada are open now. Recruiting first, the newest first:
Centre hospitalier de l'Université de Montréal (CHUM) · Sites in Canada
Ages 65+
Memorial University of Newfoundland · Sites in Canada
Ages 18+
Laval University · Sites in Canada
Ages 25–50
Lena Xiao · Sites in Canada
Ages 8–18
Laval University · Sites in Canada
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.
This study: 40 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
104 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 24 is below the median of 68 across 2,363 interventional studies indexed under Sleep Initiation and Maintenance Disorders.
Median enrollment 89 across the 96 interventional studies, 200 across the 8 observational. Of the 68 that completed or were terminated, 10 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 104 have an industry lead sponsor. The 10 most frequent:
University of Calgary is the lead sponsor of 704 studies on the registry; 197 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 2 (20%) have results posted.
University of Calgary has 7 studies filed under Sleep Initiation and Maintenance Disorders — fewer than ten, so there is no comparison to draw.
12 of the studies in Sleep Initiation and Maintenance Disorders with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06568367Phase 3Axsome Therapeutics, Inc.Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN) | 2026-12 |
| NCT04278404Duke UniversityPharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 2026-11 |
| NCT07101302Memorial University of NewfoundlandiCANSleep: Smartphone App-Based Insomnia Treatment for Cancer Survivors | 2026-11 |
| NCT06745349University of ReginaThe Sleep Course: An Online Sleep Intervention for Adults With Self-reported Sleep Difficulties | 2026-12 |
| NCT07176767Lena XiaoThe IPAD Cohort Study: Insomnia and Positive Airway Pressure Adherence in Children and Adolescents | 2026-12-31 |
Add all 12 to your calendar (.ics) → With an account.
Among the 104 studies in Sleep Initiation and Maintenance Disorders with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Fatigue, poor sleep quality, and reduced physiological recovery are common even among otherwise healthy adults. Subtle factors such as jaw position during sleep and breathing efficiency may contribute to these issues. The mandible (lower jaw) is suspended by muscles and ligaments rather than fixed joints, making it susceptible to small positional changes during sleep. Even mild misalignment of the lower jaw can reduce airway space, alter breathing mechanics, and disrupt sleep architecture, which may in turn affect autonomic regulation and recovery.
This study will evaluate whether a custom mandibular oral repositioning appliance (px3™) improves sleep quality and recovery-related physiological measures compared with a placebo oral device. The px3™ device gently advances the lower jaw during sleep, which may help maintain airway openness and support more stable breathing. The placebo device is custom-fitted but holds the jaw in a neutral position without mandibular advancement, allowing for controlled comparison of device effects.
Using a randomized crossover design, each participant will wear both the px3™ device and the placebo device during separate intervention phases, allowing participants to serve as their own control. The study will take place over approximately 12 weeks and includes baseline monitoring without any oral appliance, two intervention phases, a washout period between conditions, and a short follow-up period.
Participants will undergo non-invasive digital dental scans to fabricate two custom oral devices. Sleep, heart rate variability (HRV), and blood oxygen saturation (SpO₂) will be continuously monitored using a wrist-worn wearable device throughout the study, except during bathing or charging. Participants will also complete brief questionnaires and sleep logs to report comfort, adherence, perceived effects, and factors that may influence sleep (e.g., illness, travel, or alcohol use).
The primary outcomes of interest are changes in sleep stage distribution (including deep, light, and REM sleep), HRV, and SpO₂ when using the PX3™ device compared with the placebo device. Secondary outcomes include participant comfort, adherence, and user experience. The findings from this study will help determine whether mandibular oral repositioning may support sleep quality and physiological recovery in healthy adults.
Background and Rationale
Fatigue, stress, and burnout are increasingly prevalent among healthy, high-performance individuals. Two often-overlooked contributors are jaw misalignment (malocclusion) and over-breathing, both of which can impair respiratory efficiency, sleep quality, and physiological recovery.
The mandible is unique in the human body, suspended by muscles and ligaments rather than fixed joints. This provides a wide range of motion but makes it susceptible to misalignment during activity or sleep. Even mild malocclusion can compromise airway patency, neuromuscular coordination, and craniofacial balance. Consequences may include reduced respiratory efficiency, increased fatigue, impaired concentration, and elevated injury risk. Secondary issues from mouth-breathing and over-breathing - such as poor oxygen-carbon dioxide balance and disrupted sleep - further contribute to fatigue and suboptimal performance.
The PX3™ Mandibular Oral Repositioning Appliance is designed to advance and stabilize the lower jaw, optimizing airway openness and physiological efficiency. The device functions similarly to the airway-opening maneuver used in cardiopulmonary resuscitation, slightly bringing the mandible forward to facilitate airflow. Each PX3™ appliance is custom-fitted to align and lock opposing teeth, stabilizing the jaw during sleep or high-stress activities.
PX3™ designs are based on three physical principles:
(i) Poiseuille's Law: Increasing airway volume increases oxygen intake. (ii) Gas Exchange Law: Optimized oxygen and carbon dioxide exchange enhances physiological function.
(iii) Conservation of Energy Law: Greater oxygen availability improves mechanical efficiency.
Preliminary PX3™ testing has shown positive trends in airway efficiency, strength, balance, and endurance. In a study by Zupan et al. (2018), 25 participants demonstrated significantly faster 1.5-mile run times, greater anaerobic endurance, and higher leg-press strength when using the PX3™ device compared with a standard mouthguard or no mouthpiece. Nevertheless, the effects of this intervention on sleep quality and heart rate variability (HRV) - markers of recovery and autonomic balance - have not been evaluated in a controlled research setting.
Research Question \& Objectives:
Research Question: Does the PX3™ Mandibular Oral Repositioning Appliance improve sleep quality, heart rate variability, and blood oxygen saturation (SpO2) in healthy adults?
Objectives:
(i) To determine whether wearing the PX3™ appliance during sleep changes sleep stage distribution (deep, light, REM, awake), HRV, and SpO2 compared with a placebo device.
(ii) To evaluate participant experience, comfort, and adherence.
Study Design:
A randomized crossover design will compare the effects of the PX3™ device versus a placebo oral appliance. Each participant will complete baseline, intervention, washout, and crossover phases over an 12-week period.
Participants:
An a priori power analysis (G*Power) indicated that 19 participants are needed to detect a large effect (Cohen's d = 0.80, α = 0.05, power = 0.90). To allow for some expected attrition (\~20%), 24 participants will be recruited.
Inclusion criteria:
Procedures:
Participants meeting inclusion criteria will undergo digital oral scans (upper, lower, and occlusal) to fabricate two custom devices. All scans will be completed at Tuscany Dental Centre (11300 Tuscany Blvd NW, Suite 2078, Calgary, AB T3L 2V7) and will be performed or overseen by Dr. Cam Brauer, a licensed dentist. The iTero digital oral scanner is a non-invasive, radiation-free optical imaging device used to obtain high-resolution 3D models of a participant's teeth and oral structures. The procedure involves using a handheld scanning wand to capture sequential images of the upper and lower arches and a brief bite registration. The wand does not contact any tissues, and the scan typically takes 8-12 minutes. This procedure is widely used in clinical practice and carries minimal risk. Potential minor discomforts may include mild jaw fatigue or a brief gag reflex, but no anesthetic or radiation is involved. All scan data are securely stored, de-identified, and transmitted in accordance with the study's data-management plan and relevant privacy regulations. Scans are performed by trained dental professionals following standard infection-control procedures.
The Placebo Device (PD) is a splint in centric occlusion with no mandibular advancement. The PX3™ Device advances the mandible 50-70% of maximum protrusion to improve alignment.
Each participant will receive a wrist-worn Garmin Forerunner 245 wearable device to continuously record sleep, HRV, and SpO2, except during bathing or charging. The device will be paired to the participant's smartphone using a study-specific Garmin Connect account created by the research team that does not contain personally identifying information. Data will be synced to the smartphone and retrieved by the research team on a rolling basis. Although the device is capable of collecting GPS data, GPS information will not be accessed, downloaded, or analyzed. Only sleep, HRV, and SpO2 metrics will be retained for research purposes. Data collection will occur over an 12-week period consisting of several phases: a 4-week baseline phase during which participants wear the monitor without any oral device; Phase 1 (3 weeks), where participants are randomized to either the PX3™ or placebo device; a 1-week washout period with no device use; Phase 2 (3 weeks), during which participants switch to the alternate device; and finally, a 1-week follow-up period of continued monitoring after completing both conditions.
Participants will wear the assigned oral appliance during sleep (mandatory) and may optionally use it during daytime. At each in-person visit, they will return devices and complete a survey on comfort, adherence, and perceived effects.
Participants will also maintain a nightly sleep log documenting their subjective sleep quality and any atypical factors that could influence restfulness (e.g., alcohol consumption, excessive exercise, illness, or travel). These notes will help contextualize variations in wearable-derived sleep and recovery metrics.
Data Analysis:
Sleep stage proportions (deep, light, REM, awake), HRV, and SpO2 data will be extracted from the wearable device for baseline and intervention phases. The percentage change in each variable will be calculated as:
% Change = [(Intervention - Baseline) / Baseline] × 100%
Paired t-tests will compare mean percentage changes between PX3™ and placebo conditions for sleep, HRV, and SpO2 outcomes. Statistical significance will be set at α = 0.05.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The PX3™ Mandibular Oral Repositioning Appliance is designed to advance and stabilize the lower jaw, optimizing airway openness and physiological efficiency. The device functions similarly to the airway-opening maneuver used in cardiopulmonary resuscitation, slightly bringing the mandible forward to facilitate airflow. Each PX3™ appliance is custom-fitted to align and lock opposing teeth, stabilizing the jaw during sleep or high-stress activities. PX3™ designs are based on three physical principles: (i) Poiseuille's Law: Increasing airway volume increases oxygen intake. (ii) Gas Exchange Law: Optimized oxygen and carbon dioxide exchange enhances physiological function. (iii) Conservation of Energy Law: Greater oxygen availability improves mechanical efficiency.
Device: Mandibular Oral Repositioning Appliance
The Placebo Device is a splint in centric occlusion with no mandibular advancement. The PX3™ Device advances the mandible 50-70% of maximum protrusion to improve alignment.
Device: Mandibular Oral Repositioning Appliance
The PX3™ Mandibular Oral Repositioning Appliance is designed to advance and stabilize the lower jaw, optimizing airway openness and physiological efficiency. The device functions similarly to the airway-opening maneuver used in cardiopulmonary resuscitation, slightly bringing the mandible forward to facilitate airflow. Each PX3™ appliance is custom-fitted to align and lock opposing teeth, stabilizing the jaw during sleep or high-stress activities. PX3™ designs are based on three physical principles: (i) Poiseuille's Law: Increasing airway volume increases oxygen intake. (ii) Gas Exchange Law: Optimized oxygen and carbon dioxide exchange enhances physiological function. (iii) Conservation of Energy Law: Greater oxygen availability improves mechanical efficiency.
Total Sleep Duration
Total sleep duration will be measured using a wrist-worn Garmin Forerunner 245 wearable device. Sleep duration will be calculated as the total time classified as sleep during each recorded night across baseline and intervention phases. Unit of Measure: Minutes (or hours)
Time frame: Baseline (no oral appliance) and throughout each intervention phase while wearing the PX3™ device and the placebo device, through study completion (up to approximately 12 weeks)
Sleep Stage Proportions
Sleep stage proportions (deep sleep, light sleep, REM sleep, and awake time) will be measured using a wrist-worn Garmin Forerunner 245 wearable device. Sleep stage data will be recorded continuously during baseline and intervention phases and summarized as the proportion of total sleep time spent in each sleep stage. Unit of Measure: Percentage (%) of total sleep time
Time frame: Baseline (no oral appliance) and throughout each intervention phase while wearing the PX3™ device and the placebo device, through study completion (up to approximately 12 weeks)
Heart Rate Variability (HRV)
Heart rate variability will be measured using a wrist-worn Garmin Forerunner 245 wearable device. HRV data will be collected continuously during baseline and intervention phases and extracted for analysis using device-derived metrics. Unit of Measure: Milliseconds (ms)
Time frame: Baseline (no oral appliance) and throughout each intervention phase while wearing the PX3™ device and the placebo device, through study completion (up to approximately 12 weeks)
Blood Oxygen Saturation (SpO2)
Blood oxygen saturation (SpO₂) will be measured using a wrist-worn Garmin Forerunner 245 wearable device. SpO₂ data will be recorded during sleep periods throughout baseline and intervention phases and extracted for analysis. Unit of Measure: Percentage (%)
Time frame: Baseline (no oral appliance) and throughout each intervention phase while wearing the PX3™ device and the placebo device, through study completion (up to approximately 12 weeks)
Participant Comfort With the Device
Participant-reported comfort while wearing the device will be assessed using a survey administered after each study condition. Unit of Measure: Likert scale (as defined in the survey)
Time frame: Baseline (no oral appliance) and throughout each intervention phase while wearing the PX3™ device and the placebo device, through study completion (up to approximately 12 weeks)
Participant Adherence to Device Use
Participant adherence to wearing the device as instructed will be assessed using a self-reported survey administered after each study condition. Unit of Measure: Likert scale or percentage of prescribed wear time (as defined in the survey)
Time frame: Immediately after each intervention phase (after Condition 1 and after Condition 2)
Participant Experience Using the Device
Overall participant experience using the device will be assessed using a survey administered after each study condition. Unit of Measure: Likert scale (as defined in the survey)
Time frame: Immediately after each intervention phase (after Condition 1 and after Condition 2)
Participant-Perceived Effects of the Device
Participant-perceived effects of the device on sleep, recovery, or daily functioning will be assessed using a survey administered after each study condition. Unit of Measure: Likert scale (as defined in the survey)
Time frame: Immediately after each intervention phase (after Condition 1 and after Condition 2)
Plan to share: No — Individual participant data (IPD) will not be shared. Data collected in this study include detailed physiological and health-related measures, and sharing individual-level data could increase the risk of participant re-identification. Only aggregated, de-identified summary results will be reported and shared in publications or presentations, in accordance with institutional ethics approval and data-governance policies.
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Aug 2026, 6 months after the start.
Of 1,219 non-industry interventional studies with no phase under Sleep Initiation and Maintenance Disorders, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 35. This study's planned 6 months is below that.
Counting every sponsor, half of 1,297 studies reached it within 15 months; a quarter within 6 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sleep Initiation and Maintenance Disorders →